Companies/HLS Therapeutics Inc.

Company profile

HLS Therapeutics Inc.

OTC: HLTRF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Etobicoke, ONReports USD

#413 of 1,394 Healthcare companies by revenue40th-percentile growth

EA Score

64C

FH 66DQ —GM 56SS 64

v0.1 · 45/100 weight · provisional

↑ growth stability, Piotroski F · ↓ 3-yr revenue growth, revenue growth (YoY)

Methodology →

Revenue TTM

$55.8M

Rev growth YoY (TTM)

-1.7%

Net income (FY)

-$12.6M

Employees

Market cap

$93.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$56.5M$56.5M2025

Net income-$12.6M-$12.6M2025

Operating income-$4.2M-$4.2M2025

Total assets$137.3M$137.3M2025

Liabilities$75.7M$75.7M2025

Equity$61.6M$61.6M2025

Revenue trend

FY2018 – FY2025 · USD

$61.4M

FY18

$54.2M

FY19

$56.1M

FY20

$60.0M

FY21

$61.5M

FY22

$63.1M

FY23

$56.6M

FY24

$56.5M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

HLS Therapeutics Inc. booked $56.5M in FY2025 revenue, contracting 0.3% year over year — about the middle of the pack among Healthcare companies we track, at a -22.4% net margin.

Peers · Healthcare

CAMP4 Therapeutics Corporation27D CareCloud, Inc.73B ImmuCell Corporation63C Jushi Holdings Inc.54D

Key facts

CEOCraig Stuart Millian

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersEtobicoke, ON

ExchangeOTC: HLTRF

Employees92

IPO date2010-01-27

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.